PERSISTENCE THERAPEUTICS, INC.

Medtech · Private

SynthNode, an implantable synthetic lymph node device that generates CAR T cells ex vivo for cancer and autoimmune disease treatment

Grants
$315K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · The SynthNode Paradigm: Reimagining CAR T Cell Therapy for Improved Patient Outcomes$314,685
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2036EMBIOSYS INC.——
2037OLMEDA BIOSCIENCES LLC——
2038AIMLOXY LLC——
2039PERSISTENCE THERAPEUTICS, INC.——
2040EYESCREEN, INC.——
2041KATE ALLYN PROSTHETIC RESEARCH——
2042TEUCER DIAGNOSTICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.